Pharmaceutical News

RSS

Study shows wide geographic variation in use of 'clotbuster' for stroke treatment

It looks like a crazy quilt spread over the continent. But a new map of emergency stroke care in America shows just how much of a patchwork system we still have for delivering the most effective stroke treatment.

27 Jun 2015

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.

26 Jun 2015

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs.

26 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed.

26 Jun 2015

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.

26 Jun 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

As a tumor grows, its cancerous cells ramp up an energy-harvesting process to support its hasty development. This process, called autophagy, is normally used by a cell to recycle damaged organelles and proteins, but is also co-opted by cancer cells to meet their increased energy and metabolic demands.

26 Jun 2015

Pilot antibiotic program at pediatric long-term care facility decreases use of topical antibiotic

A pilot antibiotic stewardship program at a pediatric long-term care facility brought about a 59 percent decrease in use of a topical antibiotic and an 83 percent decrease in orders for antibiotics without proper documentation during a six-month period, according to a new study.

26 Jun 2015

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.

25 Jun 2015

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia.

25 Jun 2015

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration.

25 Jun 2015

Study: Cellular respiration separates effects of bactericidal and bacteriostatic antibiotics

Antibiotics are the mainstay in the treatment of bacterial infections, and together with vaccines, have enabled the near eradication of infectious diseases like tuberculosis, at least in developed countries.

25 Jun 2015

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

GlaxoSmithKline announced today that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18).

25 Jun 2015

FDA accepts proposed brand name Invossa for TissueGene-C

TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.

24 Jun 2015

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein (branch retinal vein occlusion, BRVO).

24 Jun 2015

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.

23 Jun 2015

Pioglitazone drug significantly decreases risk of dementia

Patients with type 2 diabetes have a dysfunctional sugar metabolism because the essential hormone insulin does not work effectively. Once the disease reaches an advanced stage, the body stops producing insulin altogether, which means that it has to be administered externally.

23 Jun 2015

Drugs used against impotence does not increase risk of malignant melanoma

Using drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association.

23 Jun 2015

Pharmaceutical News

Study shows wide geographic variation in use of 'clotbuster' for stroke treatment

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

Pilot antibiotic program at pediatric long-term care facility decreases use of topical antibiotic

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Study: Cellular respiration separates effects of bactericidal and bacteriostatic antibiotics

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

FDA accepts proposed brand name Invossa for TissueGene-C

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Generic heart disease drugs show promise in patients affected by Ebola virus

Pioglitazone drug significantly decreases risk of dementia

Drugs used against impotence does not increase risk of malignant melanoma

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News